{"id":23141,"date":"2024-04-16T09:33:50","date_gmt":"2024-04-16T07:33:50","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=23141"},"modified":"2025-03-27T11:03:01","modified_gmt":"2025-03-27T10:03:01","slug":"cell-and-gene-therapies","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/","title":{"rendered":"Cell and gene therapies"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Every month, MabDesign’s market analyses provide you with an overview of market dynamics and projects<\/span> in development for a specific indication or technology, to help you better understand the constantly evolving market for biomedicines and biomanufacturing.<\/span> <\/p>\n

The first edition of our Innovations for Cell and Gene Therapies (ICGT)<\/a> congress, organized in collaboration with the <\/span>French Society of Cell and Gene Therapy (SFTCG) <\/a> will take place on May 22, 2024, in Paris. <\/span>In the meantime, this month we share an overview of the cell and gene therapy market. <\/span> <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Advanced therapy medicinal products (ATMPs) <\/a>explore new therapeutic approaches based on genome modification or the manipulation of patient or healthy donor cells. They represent a major transition from traditional medicine to a more personalized, targeted approach. These innovative products are accelerating the development of biotherapies, and currently account for around a third of all biopharmaceuticals under development <\/strong>. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The market for in vivo gene therapy<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In vivo<\/i> gene therapy products (excluding genetically modified cell therapies such as CAR-T) are few on the market, with just 12 products currently available<\/strong>. On the other hand, the pipeline is quite extensive, with 2107 gene therapies in development<\/strong>. The vast majority of projects are in the early stages of development, with only 15% in clinical phases<\/b>. In terms of vectors used, viral vectors<\/b>, and in particular AAVs(adeno-associated viruses<\/i>), are the technology most frequently chosen for projects in the pipeline. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
in vivo gene therapies on the market*.<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
products under development*<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

*excluding genetically modified cell therapies <\/em><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

In vivo gene therapies in development, by phase<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/h5><\/div>\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Vector types (pipeline)<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"vecteurs\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

AV: adenovirus; AAV: adeno-associated virus; LNP: lipid nanoparticles<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The market for gene-modified cell therapies <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Gene-modified cell therapies (or ex-vivo<\/i> gene therapies), such as CAR-T cells, are still few on the market: there are currently 17<\/b> products available<\/strong>. By contrast, the pipeline is very rich, with over 3,000<\/b> genetically modified cell therapies in development<\/strong>. Projects are in relatively advanced stages of development, with 36% in clinical phases<\/b>. In terms of targeted indications, the first three are blood cancers <\/b>: diffuse large B-cell lymphoma, acute B-cell lymphocytic leukemia, and relapsed\/refractory multiple myeloma. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
gene-modified cell therapies on the market<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
products in development<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Gene-modified cell therapies in development, by phase<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/h5><\/div>\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Top 3 indications (pipeline)<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"gene-modified\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The Cell Therapy Market <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

More cell therapy drugs are on the market: there are currently 41 marketed products<\/strong> and 1,894 cell therapies in development<\/strong>. Compared with gene therapies, 46.1% of cell therapies in development are in clinical phases<\/b>. The most targeted therapeutic areas are oncology, the central nervous system and infectious diseases. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
cell therapies on the market<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
products in development<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Cell therapies in development, by phase<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/h5><\/div>\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Top 3 therapeutic areas (pipeline)<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"aires\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Download our infographic<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Cell and gene therapy market<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"th\u00e9rapie\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/path><\/svg><\/span>Download in .pdf format<\/span><\/span><\/small><\/span><\/a>\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Want to find out more? <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"ICGT,\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In 2024, in collaboration with the SFTCG, MabDesign is launching the first edition of the <\/i>Innovations for Cell and Gene Therapies (ICGT) congress<\/a>! You can<\/i><\/span><\/span>register<\/a>now, or contact us<\/a> for more information.<\/i><\/span><\/span> <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team<\/a> of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services<\/a>, including our marketing and strategic analyses<\/a>, if you’d like to find out more!<\/i><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tContact us<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sources: MabDesign, GlobalData<\/p>\n

Date – March 2024<\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

The first edition of our Innovations for Cell and Gene Therapies (ICGT) congress, organized in collaboration with the Soci\u00e9t\u00e9 Fran\u00e7aise de Th\u00e9rapie Cellulaire et g\u00e9nique (SFTCG), will take place on May 22, 2024, in Paris. In the meantime, this month we share an overview of the cell and gene therapy market. <\/p>\n","protected":false},"author":4,"featured_media":23119,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[88,119],"tags":[91,163,257,118,117,141,120],"class_list":["post-23141","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bio-hub-en","category-market-analysis-en","tag-atmp","tag-biomedicaments-en","tag-cell-and-gene-therapy","tag-cell-therapy","tag-gene-therapy","tag-market","tag-pipeline-en"],"yoast_head":"\nMarket Cell and gene therapies - MabDesign<\/title>\n<meta name=\"description\" content=\"In conjunction with our first congress on the subject, this month we present an overview of the gene and cell therapy market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Market Cell and gene therapies - MabDesign\" \/>\n<meta property=\"og:description\" content=\"In conjunction with our first congress on the subject, this month we present an overview of the gene and cell therapy market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-16T07:33:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-27T10:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1414\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anabelle Perrier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anabelle Perrier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/\"},\"author\":{\"name\":\"Anabelle Perrier\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918\"},\"headline\":\"Cell and gene therapies\",\"datePublished\":\"2024-04-16T07:33:50+00:00\",\"dateModified\":\"2025-03-27T10:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/\"},\"wordCount\":542,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png\",\"keywords\":[\"ATMP\",\"biom\u00e9dicaments\",\"Cell and Gene therapy\",\"cell therapy\",\"gene therapy\",\"market\",\"pipeline\"],\"articleSection\":[\"Bio-hub\",\"Market analysis\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/\",\"name\":\"Market Cell and gene therapies - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png\",\"datePublished\":\"2024-04-16T07:33:50+00:00\",\"dateModified\":\"2025-03-27T10:03:01+00:00\",\"description\":\"In conjunction with our first congress on the subject, this month we present an overview of the gene and cell therapy market.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png\",\"width\":1414,\"height\":2000,\"caption\":\"th\u00e9rapie cellulaire, th\u00e9rapie g\u00e9nique, march\u00e9, pipeline, ICGT\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cell and gene therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918\",\"name\":\"Anabelle Perrier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g\",\"caption\":\"Anabelle Perrier\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/anabelle-perriermabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Market Cell and gene therapies - MabDesign","description":"In conjunction with our first congress on the subject, this month we present an overview of the gene and cell therapy market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Market Cell and gene therapies - MabDesign","og_description":"In conjunction with our first congress on the subject, this month we present an overview of the gene and cell therapy market.","og_url":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/","og_site_name":"MabDesign","article_published_time":"2024-04-16T07:33:50+00:00","article_modified_time":"2025-03-27T10:03:01+00:00","og_image":[{"width":1414,"height":2000,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png","type":"image\/png"}],"author":"Anabelle Perrier","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Anabelle Perrier","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/"},"author":{"name":"Anabelle Perrier","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918"},"headline":"Cell and gene therapies","datePublished":"2024-04-16T07:33:50+00:00","dateModified":"2025-03-27T10:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/"},"wordCount":542,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png","keywords":["ATMP","biom\u00e9dicaments","Cell and Gene therapy","cell therapy","gene therapy","market","pipeline"],"articleSection":["Bio-hub","Market analysis"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/","url":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/","name":"Market Cell and gene therapies - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png","datePublished":"2024-04-16T07:33:50+00:00","dateModified":"2025-03-27T10:03:01+00:00","description":"In conjunction with our first congress on the subject, this month we present an overview of the gene and cell therapy market.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/MabDesign-Market-analysis-CellGene-therapies-April-2024-.png","width":1414,"height":2000,"caption":"th\u00e9rapie cellulaire, th\u00e9rapie g\u00e9nique, march\u00e9, pipeline, ICGT"},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/cell-and-gene-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Cell and gene therapies"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918","name":"Anabelle Perrier","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g","caption":"Anabelle Perrier"},"url":"https:\/\/mabdesign.fr\/en\/author\/anabelle-perriermabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/23141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=23141"}],"version-history":[{"count":8,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/23141\/revisions"}],"predecessor-version":[{"id":23655,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/23141\/revisions\/23655"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/23119"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=23141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=23141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=23141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}